GABAA Receptor Delta Antibody [N151/3 (Formerly sold as S151-3)]
GABAA Receptor Delta Antibody [N151/3 (Formerly sold as S151-3)] is a mouse monoclonal antibody directed against GABAA Receptor Delta, offered by Assay Genie for research applications. Reported applications include WB, ICC/IF and AM. Reported reactivity: Human, Mouse and Rat. Supplied as IgG2a, purified by Protein G.
The GABA-A receptor delta subunit (GABRD) is a specialized component of the GABA-A receptor family, which comprises fast-acting ligand-gated ion channels responsible for inhibitory neurotransmission in the brain. Unlike synaptic GABA-A receptors, delta-containing receptors are primarily located extrasynaptically and mediate tonic inhibition—providing a continuous inhibitory tone that stabilizes neural networks and prevents hyperexcitability. GABRD is highly expressed in brain regions involved in cognition and emotional regulation, such as the thalamus, hippocampus, and cerebellum. Its unique role in maintaining baseline inhibitory control makes it a critical factor in neurological health. Dysregulation of GABRD has been implicated in a range of disorders, including epilepsy, anxiety, and sleep disturbances. More recently, its involvement in neurodegenerative diseases has gained attention, particularly in conditions like Alzheimer’s disease, where impaired tonic inhibition contributes to network dysfunction, excitotoxicity, and cognitive decline. Targeting GABRD-containing receptors offers a promising therapeutic strategy for restoring inhibitory balance and protecting against neurodegeneration. As research advances, GABRD is emerging as both a biomarker and a molecular target in the development of precision treatments for GABAergic dysfunction in aging and disease. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.
Product Name:
GABAA Receptor Delta Antibody [N151/3 (Formerly sold as S151-3)]